DailyMed Label: Dysport

DailyMed Label: Dysport

2023

DailyMed Prescription

Dysport

Botulinum Toxin Type A

Galderma Laboratories, L.P.

NDC: 0299-5962

NDC: 0299-5962

NDC: 0299-5962

Botulinum toxin type A, the active ingredient in DYSPORT, is a purified neurotoxin type A complex produced by fermentation of the bacterium Clostridium botulinum type A, Hall Strain. It is purified from the culture supernatant by a series of precipitation, dialysis, and chromatography steps. The neurotoxin complex is composed of the neurotoxin, hemagglutinin proteins and non-toxin non-hemagglutinin protein. DYSPORT® (abobotulinumtoxinA) for injection is a sterile, lyophilized powder supplied in a single-dose vial for reconstitution intended for intramuscular injection. Each vial contains 300 Units or 500 Units of lyophilized abobotulinumtoxinA, human serum albumin (125 mcg) and lactose (2.5 mg). DYSPORT   may contain trace amounts of cow's milk proteins [ see Contraindications (4)  and Warnings and Precautions (5.3) ].                     ]. The primary release procedure for DYSPORT uses a cell-based potency assay to determine the potency relative to a reference standard.  The assay and reference material are specific to DYSPORT. One unit of DYSPORT corresponds to the calculated median lethal intraperitoneal dose (LD 50 ) in mice.  Due to specific details of the assay system, such as vehicle, dilution scheme and laboratory protocols, Units of biological activity of DYSPORT cannot be converted into Units of any other botulinum toxin or any toxin assessed with any other specific assay method.

DYSPORT is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for: the treatment of cervical dystonia in adults ( 1.1 ) the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults < 65 years of age ( 1.2 ) The treatment of  spasticity in patients 2 years of age and older ( 1.3 ) DYSPORT is indicated for the treatment of cervical dystonia in adults. DYSPORT is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults less than 65 years of age. DYSPORT is indicated for the treatment of spasticity in patients 2 years of age and older.

Preparation of DYSPORT Solution for Administration ( 2.2 ) Once reconstituted, store in original container in a refrigerator 2°C to 8°C (36°F to 46°F)  and use within 24 hours Do not freeze after reconstitution Reconstitution instructions are specific for the 300 Unit and 500 Unit vials  Reconstituted DYSPORT is intended for intramuscular injection only. After reconstitution, DYSPORT should be used for only one injection session and for only one patient. Cervical Dystonia ( 2.3 ) • Initial dose is 500 Units given intramuscularly as a divided dose among the affected muscles • Re-treatment every 12 to 16 weeks or longer, as necessary, based on return of clinical symptoms with doses administered between 250 and 1000 Units to optimize clinical benefit • Re-treatment should not occur in intervals of less than 12 weeks • Titrate in 250 Unit steps according to patient's response Glabellar Lines ( 2.4 ) Administer a total dose of 50 Units, divided in five equal aliquots of 10 Units each, intramuscularly to affected muscles to achieve clinical effect Re-treatment should be administered no more frequently than every 3 months Spasticity in Adults ( 2.5 ) Select dose based on muscles affected, severity of spasticity, and treatment and adverse reaction history botulinum toxins Dosing for upper limb spasticity: between 500 Units and 1000 Units Dosing for lower limb spasticity: up to 1500 Units The maximum recommended total dose per treatment session (upper and lower limb combined) in adults is 1500 Units  Re-treatment, based on return of clinical symptoms, should not occur in intervals of less than 12 weeks Spasticity in Pediatric Patients ( 2.6 ) Select dose based on the affected muscle, severity of spasticity, and treatment and adverse reaction history with all botulinum toxins. Recommended dosing for upper limb spasticity: 8 Units/kg to 16 Units/kg per limb.  The maximum recommended total dose administered per treatment session must not exceed 16 Units/kg or 640 Units, whichever is lower. Recommended dosing for lower limb spasticity: 10 Units/kg to 15 Units/kg per limb.  Total dose per treatment session must not exceed 15 Units/kg for unilateral lower limb injections, 30 Units/kg for bilateral injections, or 1000 Units, whichever is lower. The maximum recommended total dose per treatment session is 30 Units/kg or 1000 Units, whichever is lower.  Re-treatment, based on return of clinical symptoms, should not occur in intervals of less than 3 months. The potency units of DYSPORT are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of DYSPORT cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method [ see Warnings and Precautions (5.2) and  Description (11) ].  Reconstituted DYSPORT is intended for intramuscular injection only. DYSPORT is supplied as a dry powder, in single-dose 300 Unit and 500 Unit vials, which must be reconstituted with preservative-free 0.9% Sodium Chloride Injection, USP using aseptic technique prior to intramuscular injection.  Table 1 provides dilution instructions for the 300 Unit and 500 Unit vials, depending on the desired final concentration.  The desired final concentration after dilution varies depending on the indication (see Table 2 for the recommended solution concentration after dilution). Table 1: Dilution Instructions for DYSPORT Vials (500 Units and 300 Units) Diluent Preservative-free 0.9% Sodium Chloride Injection, USP Only   per 500 Unit Vial Resulting Dose Unites per 0.1 mL DIluent per 300 Unit Vial Resulting Dose Units per 0.1 mL 1 mL 50 Units 0.6 mL 50 Units 2 mL 25 Units -- -- 2.5 mL 20 Units 1.5 mL 20 Units -- -- 2.5 mL 12 Units 5 mL ‡ 10 Units 3 mL 10 Units Note: These dilutions are calculated for an injection volume of 0.1 mL.  A decrease or increase in the DYSPORT dose is also possible by administering a smaller or larger injection volume (i.e., 0.05 mL (50% decrease in dose), 0.08% (20% decrease in dose) or 0.15 mL (50% increase in dose)). ‡ When using 5 mL of diluent for a 500 Unit vial of DYSPORT, no more than 2.5 mL of 0.9% Sodium Chloride Injection, USP should be introduced into the vial.  Complete the following steps: Reconstitute a 500 Unit vial of DYSPORT with 2.5 mL of Preservative-free 0.9% Sodium Chloride Injection, USP, gently mix, and set the vital aside. Withdraw 2.5 mL of Preservative-free 0.9 Sodium Chloride Infection, USP into a 5 mL syringe Take the 5 mL syringe with 2.5 ml Preservative-free Sodium Chloride Injection, USP and draw up the DYSPORT solution from the reconstituted vial without inverting and mix gently.  The resulting concentration will be 10 units/0.1 mL Use immediately after reconstitution in the syringe.  Dispose of any unused 0.9% Sodium Chloride Injection, USP. Using an appropriately sized sterile syringe, needle and aseptic technique, draw up the required amount of sterile, preservative-free 0.9% Sodium Chloride Injection, USP (see Table 1 ). Insert the needle into the DYSPORT vial. The partial vacuum will begin to pull the saline into the vial. Any remaining required saline should be expressed into the vial manually. Do not use the vial if no partial vacuum is observed. Swirl gently to dissolve. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.    Reconstituted DYSPORT should be a clear, colorless solution, free of particulate matter, otherwise it should not be injected. Expel any air bubbles in the syringe barrel. Remove the needle used to reconstitute the product and attach an appropriately sized new sterile needle for injection. After reconstitution, DYSPORT should be used for only one injection session and for only one patient. Discard any unused portion. Once reconstituted, unused DYSPORT may be stored in the original container, in a refrigerator at 2°C to 8°C (36°F to 46°F), protected from light for up to 24 hours until time of use. It must be discarded if not used within 24 hours. Do not freeze reconstituted DYSPORT. Discard the vial and needle in accordance with local regulations. Table 2: Recommended Solution Concentration and Dosing Range of DYSPORT by Indication Indication Recommended Concentration Recommended DYSPORT Dose Cervical Dystonia, Adults 50 Units/0.1 mL or 25 Units/0.1 mL 500 Units to 1000 Units Glabellar Lines, Adults 12 Units/0.1 mL or 20 Units/0.1 mL 50 Units, divided in five equal aliquots of 10 Units (0.08 mL) each or 50 Units, divided in five equal aliquots of 10 Units (0.05 mL) each Spasticity, Adults* 10 Units/0.1 mL or 20 Units/0.1 mL Upper Limb: 500 Units to 1000 Units Lower Limb: 1000 Units to 1500 Units Maximum total dose per treatment session = 1500 Units Spasticity, Pediatric Patients ‡ 20 Units/0.1 mL or 50 Units/0.1 mL** Upper Limb: 8 Units/kg to 16 Units/kg per limb Maximum total dose per treatment session = 16 Units/kg or 640 Units, whichever is lower   Lower Limb: 10 Units/kg to 15 Units/kg per limb Maximum total dose per treatment session for unilateral limb injections = 15 Units/kg or 1000 Units, whichever is lower Maximum total dose per treatment session for bilateral limb injections = 30 Units/kg or 1000 Units, whichever is lower   Maximum total dose per treatment session = 30 Units/kg or 1000 Units, whichever is lower * No more than 1 mL should generally be administered at any single injections site ‡ No more than 0.5 mL of DYSPORT should be administered in any single injection site ** Further dilution with preservative-free 0.9% Sodium Chloride Injection, USP, may be required to achieve the final volume for injection. The recommended initial dose of DYSPORT for the treatment of cervical dystonia in adults is 500 Units given intramuscularly as a divided dose among affected muscles in patients with or without a history of prior treatment with botulinum toxin. (A description of the average DYSPORT dose and percentage of total dose injected into specific muscles in the pivotal clinical trials can be found in Table 15 of Section 14.1, Clinical Studies – Cervical Dystonia.) Limiting the dose injected into the sternocleidomastoid muscle may reduce the occurrence of dysphagia. Clinical studies with DYSPORT in cervical dystonia suggest that the peak effect occurs between two and four weeks after injection. Simultaneous guided injection of DYSPORT with EMG and/or ultrasound may be helpful in locating active muscles. Dose Modification Where dose modification is necessary for the treatment of cervical dystonia, uncontrolled open-label studies suggest that dose adjustment can be made in 250 Unit steps according to the individual patient's response, with re-treatment every 12 weeks or longer, as necessary, based on return of clinical symptoms. Uncontrolled open-label studies also suggest that the total dose administered in a single treatment should be between 250 Units and 1000 Units. Re-treatment, if needed, should not occur in intervals of less than 12 weeks. Doses above 1000 Units have not been systematically evaluated. The dose of DYSPORT for the treatment of glabellar lines in adults is a total of 50 Units given intramuscularly in five equal aliquots of 10 Units each to achieve clinical effect (see Figure 1 ). The clinical effect of DYSPORT may last up to four months. Repeat dosing in  clinical studies demonstrated continued efficacy with up to four repeated administrations. It should be administered no more frequently than every three months. When used for re-treatment, DYSPORT should be reconstituted and injected using the same techniques as the initial treatment. Injection Technique Glabellar facial lines arise from the activity of the lateral corrugator and vertical procerus muscles. These can be readily identified by palpating the tensed muscle mass while having the patient frown. The corrugator depresses the skin creating a "furrowed" vertical line surrounded by tensed muscle (i.e., frown lines). The location, size, and use of the muscles vary markedly among individuals. Physicians administering DYSPORT must understand the relevant neuromuscular and/or orbital anatomy of the area involved and any alterations to the anatomy due to prior surgical procedures. Risk of ptosis can be mitigated by careful examination of the upper lid for separation or weakness of the levator palpebrae muscle (true ptosis), identification of lash ptosis, and evaluation of the range of lid excursion while manually depressing the frontalis to assess compensation. In order to reduce the complication of ptosis, the following steps should be taken: Avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes. Medial corrugator injections should be placed at least 1 centimeter above the bony supraorbital ridge. Ensure the injected volume/dose is accurate and where feasible kept to a minimum. Do not inject toxin closer than 1 centimeter above the central eyebrow. To inject DYSPORT, advance the needle through the skin into the underlying muscle while applying finger pressure on the superior medial orbital rim. Inject patients with a total of 50 Units in five equally divided aliquots. Using an appropriately sized needle, inject 10 Units of DYSPORT into each of five sites, two in each corrugator muscle, and one in the procerus muscle (see Figure 1 ). Figure 1 Figure 1 Dosing in initial and subsequent treatment sessions should be tailored to the individual based on the size, number and location of muscles involved, severity of spasticity, the presence of local muscle weakness, the patient's response to previous treatment, and/or adverse reaction history with botulinum toxins.                                   No more than 1 mL should generally be administered at any single injection site.  The maximum recommended total dose (upper and lower limb combined) of DYSPORT for the treatment of spasticity in adults is 1500 Units.                                  Although actual location of the injection sites can be determined by palpation, the use of injection guiding technique (e.g., electromyography, electrical stimulation, or ultrasound) is recommended to target the injection sites. Upper Limb Spasticity In the clinical trial that assessed the efficacy and safety of DYSPORT for treatment of upper limb spasticity in adults  [ see Clinical Studies (14.3) ],  doses of 500 Units and 1000 Units were divided among selected muscles at a given treatment session (see Table 3 and Figure 2 ). Table 3: DYSPORT Dosing by Muscle for Upper Limb Spasticity in Adults Muscles Injected Recommended Dose DYSPORT Recommended Number of Injection(s) per Muscle Flexor carpi radialis (FCR) Flexor carpi ulnaris (FCU) 100 Units to 200 Units 100 Units to 200 Units 1 to 2 1 to 2 Flexor digitorum profundus (FDP) Flexor digitorum superficialis (FDS) 100 Units to 200 Units 100 Units to 200 Units 1 to 2 1 to 2 Brachialis Brachioradialis Biceps Brachii (BB) Pronator Teres 200 Units to 400 Units 100 Units to 200 Units 200 Units to 400 Units 100 Units to 200 Units 1 to 2 1 to 2 1 to 2 1                                                                                                    Figure 2: Muscles for Injection for Upper Limb Spasticity in Adults                                                  Repeat DYSPORT treatment should be administered when the effect of a previous injection has diminished, but no sooner than 12 weeks after the previous injection. A majority of patients in clinical studies were retreated between 12-16 weeks; however some patients had a longer duration of response (i.e. 20 weeks). The degree and pattern of muscle spasticity at the time of re-injection may necessitate alterations in the dose of DYSPORT and muscles to be injected. Clinical improvement may be expected one week after administration of DYSPORT. Figure 2 Lower Limb Spasticity                           In the clinical trial that assessed the efficacy and safety of DYSPORT for treatment of lower limb spasticity in adults [ see Clinical Studies (14.3) ], doses of 1000 Units and 1500 Units were divided among selected muscles at a given treatment session (see Table 4 and Figure 3).                               Table 4: DYSPORT Dosing by Muscle for Lower Limb Spasticity in Adults Muscles Injected Recommended DYSPORT Dose Recommended Number of Injection Sites per Muscle Distal Muscles Gastrocnemius    Medial head 100 Units to 150 Units 1    Lateral head 100 Units to 150 Units 1 Soleus 330 Units to 500 Units 3 Tibialis posterior 200 Units to 300 Units 2 Flexor digitorum longus 130 Units to 200 Units 1 to 2 Flexor halluces longus 70 Units to 200 Units 1 Figure 3: Muscle for Injection for Lower Limb Spasticity in Adults Repeat DYSPORT treatment should be administered when the effect of a previous injection has diminished, but no sooner than 12 weeks after the previous injection.  A majority of patients in clinical studies were retreated between 12-16 weeks.  The degree and pattern of muscle spasticity at the time of re-injection may necessitate alterations in the dose of DYSPORT  and muscles to be injected. DYSPORT dosing for spasticity in pediatric patients is based on Units per kilogram of body weight. To calculate the total units of DYSPORT required for treatment of one limb, select the dose of DYSPORT in Units/kg and the body weight (kg) of the patient (see Tables 5 and 6). Dosing in initial and sequential treatment sessions should be tailored to the individual patient based on the size, number and location of muscles involved, severity of spasticity, the presence of local muscle weakness, the patient’s response to previous treatment, and/or adverse reaction history with botulinum toxins.   No more than 0.5 mL should generally be administered at any single injection site. The maximum recommended total dose  of DYSPORT in a single treatment session for spasticity in pediatric patients 2 years or older is 30 Units/kg or 1000 Units in a 3-month interval.   Although actual location of the injection sites can be determined by palpation, the use of injection guiding technique (e.g., electromyography or electrical stimulation, or ultrasound) is recommended to target the injection sites.   Upper Limb Spasticity in Pediatric Patients 2 Years of Age and Older In the clinical trial that assessed the efficacy and safety of DYSPORT for treatment of upper limb spasticity in pediatric patients 2 years of age or older with a weight of at least 10 kg [ see Clinical Studies (14.4) ], doses of 8 Units/kg or 16 Units/kg were divided among selected muscles of the target upper limb at a given treatment session (see Table 5 and Figure 4).   Table 5 describes the recommended Units/kg dose of DYSPORT per muscle. The maximum recommended total dose of DYSPORT administered for  treatment  of upper limb spasticity must not exceed 16 Units/kg or 640 Units, whichever is lower. Table 5: DYSPORT Dosing by Muscle for Upper Limb Spasticity in Pediatric Patients Muscle Recommended Dose Range per muscle per upper limb (units/kg Body Weight) Number of injection sites per muscle Brachialis 3 Units/kg to 6 Units/kg Up to 2 Brachioradialis 1.5 Units/kg to 3 Units/kg 1 Biceps brachii 3 Units/kg to 6 Units/kg Up to 2 Pronator teres 1 Units/kg to 2 Units/kg 1 Prontator quadratus 0.5 Unit/kg to 1 Units/kg 1 Flexor carpi radialis (FCR) 2 Units/kg to 4 Units/kg Up to 2 Flexor carpi ulnaris (FCU) 1.5 Units/kg to 3 Units/kg 1 Flexor digitorum profundus (FDP) 1 Units/kg to 2 Units/kg 1 Flexor digitorum superficialis (FDS) 1.5 Units/kg to 3 Units/kg Up to 4 Total dose 8 Units/kg to 16 Units/kg in upper limbs (and not exceeding 640 Units) Figure 4: Muscles for Injection for Upper Limb Spasticity in Pediatric Patients Repeat DYSPORT treatment should be administered when the effect of a previous injection has diminished but no sooner than 16 weeks after the previous injection. A majority of patients in the clinical study were retreated between 16-28 weeks; however, some patients had a longer duration of response (i.e., 34 weeks or more). The degree and pattern of muscle spasticity at the time of re-injection may necessitate alterations in the dose of DYSPORT and muscles to be injected. Lower Limb Spasticity in Pediatric Patients 2 Years of Age and Older In the clinical trial that assessed the efficacy and safety of DYSPORT for treatment of lower limb spasticity in pediatric patients 2 years of age or older [see Clinical Studies (14.4)] , doses of 10 Units/kg to 15 Units/kg were divided among selected muscles of the target lower limb at a given treatment session (see Table 6 and Figure 5). Table 6 describes the recommended Units/kg dose of DYSPORT per muscle of the Gastrocnemius-Soleus Complex (GSC). The recommended total DYSPORT dose per treatment session is 10 Units/kg to 15 Units/kg for unilateral lower limb injections or 20 Units/kg to 30 Units/kg for bilateral lower limb injections. However, the total dose of DYSPORT administered in a 3-month interval must not exceed 15 Units/kg for unilateral lower limb injections, 30 Units/kg for bilateral lower limb injections, or 1000 units, whichever is lower. The total dose administered should be divided between the affected spastic muscles of the lower limb(s). When possible, the dose should be distributed across more than 1 injection site in any single muscle (see Table 6). Table 6. DYSPORT Dosing by Muscle for Lower Limb Spasticity in Pediatric Patients Muscle Injected Recommended DYSPORT Dose Range per muscle per leg (Units/kg Body Weight) Recommended number of injections per muscle Gastrocnemius 6 Units/kg to 9 Units/kg  the listed individual doses to be injected in the muscles can be used within the range mentioned without exceeding 15 Units/kg total dose for unilateral injection or 30 Units/kg for bilateral injections or 1000 Units whichever is lower. Up to 4 Soleus 4 Units/kg to 6 Units/kg Up to 2 Total 10 Units/kg to 15 Units/kg divided across both muscles Up to 6 Figure 5: Muscles for Injection for Lower Limb Spasticity in Pediatric Patients   Although actual location of the injection sites can be determined by palpation, the use of injection guiding technique (e.g. electromyography or electrical stimulation or ultrasound) is recommended to target the injection sites. Repeat DYSPORT treatment should be administered when the effect of a previous injection has diminished but no sooner than 12 weeks after the previous injection.  A majority of patients in the clinical studies were retreated between 16-22 weeks, however; some had a longer duration of response.  The degree and pattern of muscle spasticity and overall clinical benefit at the time of re-injection may necessitate alterations in the dose of DYSPORT and muscles to be injected. The safety and effectiveness of DYSPORT injected into proximal muscles of the lower limb for the treatment of spasticity in pediatric patients has not been established.

For injection: 300 Units or 500 Units of lyophilized powder in a single-dose vial for reconstitution with preservative-free 0.9% Sodium Chloride Injection, USP. • For Injection: 300 Units or 500 Units lyophilized powder in a single-dose vial ( 3 )

DYSPORT is contraindicated in patients with: Known hypersensitivity to any botulinum toxin products, cow's milk protein, or to any of the components in the formulation [ see Warnings and Precautions (5.3) ] .  This product may contain trace amounts of cow's milk protein [ see Description (11) ] . Infection at the proposed injection site(s). •  Hypersensitivity to:     • any botulinum toxin product or excipients ( 4 , 5.3 )     • cow's milk protein ( 4 , 5.3 ) •  Infection at the proposed injection site(s) ( 4 )

The potency units of DYSPORT are not interchangeable with other preparations of botulinum toxin products ( 5.2 ) Immediate medical attention may be required in cases of respiratory, speech or swallowing difficulties ( 5.4 ) Recommended dose and frequency of administration should not be exceeded ( 5.5 ) Dry eye may occur with glabellar line treatment; if symptoms persist, consider referring patient to an ophthalmologist ( 5.6 ) Concomitant neuromuscular disorder may exacerbate clinical effects of treatment ( 5.7 ) Postmarketing safety data from DYSPORTand other approved botulinum toxins suggest that botulinum toxin effects may, in some cases, be observed beyond the site of local injection. The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening and there have been reports of death related to spread of toxin effects. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses and approved indications, symptoms consistent with spread of toxin effect have been reported at doses comparable to or lower than the maximum recommended total dose. The potency Units of DYSPORT are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of DYSPORT cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method [see Description (11)]. Serious hypersensitivity reactions have been reported with DYSPORT. Hypersensitivity reactions include anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea. If such a serious hypersensitivity reaction occurs, discontinue further injection of DYSPORT and institute appropriate medical therapy immediately. Treatment with DYSPORT and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved [ see Boxed Warning and Warnings and Precautions (5.2) ] . Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several weeks and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. Treatment of cervical dystonia with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been post-marketing reports of serious breathing difficulties, including respiratory failure. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin [see Boxed Warning, Warnings and Precautions (5.2 ), Adverse Reactions (6.1 ), Clinical Pharmacology (12.2 )]. Caution should be exercised when administering DYSPORT to patients with surgical alterations to the facial anatomy, marked facial asymmetry, inflammation at the injection site(s), ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin [ see Dosage and Administration (2.4) ] or the inability to substantially lessen glabellar lines by physically spreading them apart [ see Clinical Studies (14.2) ] . Do not exceed the recommended dosage and frequency of administration of DYSPORT.  In clinical trials, subjects who received a higher dose of DYSPORT   had an increased incidence of eyelid ptosis. Dry eye has been reported with the use of DYSPORT in the treatment of glabellar lines [see Adverse Reactions (6.3)]. Reduced tear production, reduced blinking, and corneal disorders, may occur with use of botulinum toxins, including DYSPORT.   If symptoms of dry eye (e.g., eye irritation, photophobia, or visual changes) persist, consider referring patient to an opththalmologist [ see Boxed Warning and Warnings and Precautions 5.2 ]. Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis or neuromuscular junction disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of DYSPORT [ see Adverse Reactions (6.1) ] . This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products. The possibility of an immune reaction when injected intradermally is unknown. The safety of DYSPORT for the treatment of hyperhidrosis has not been established. DYSPORT is approved only for intramuscular injection. Caution should be exercised when DYSPORT is used where the targeted muscle shows excessive weakness or atrophy.

The following serious adverse reactions are discussed below and elsewhere in labeling:

Concomitant use of DYSPORT and aminoglycosides or other agents interfering with neuromuscular transmission or muscle relaxants, should be observed closely because the effect of DYSPORT may be potentiated (7.1, 7.4) Anticholinergic drugs may potentiate systemic anticholinergic effects (7.2) The effect of administering different botulinum neurotoxins during the course of treatment with DYSPORT is unknown (7.3) Co-administration of DYSPORT and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents) should only be performed with caution because the effect of the botulinum toxin may be potentiated.  If co-administered, observe the patient closely. Use of anticholinergic drugs after administration of DYSPORT may potentiate systemic anticholinergic effects such as blurred vision. The effect of administering botulinum neurotoxin products including DYSPORT, at the same time or within several months of each other is unknown. Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of DYSPORT.

Administer DYSPORT with care in elderly patients, reflecting the greater frequency of concomitant disease and other drug therapy ( 8.5 ) Risk Summary There are no adequate and well-controlled clinical studies with DYSPORT in pregnant women. DYSPORT should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. DYSPORT produced embryo-fetal toxicity in relation to maternal toxicity when given to pregnant rats and rabbits at doses lower than or similar to the maximum recommended human dose (MRHD) of 1000 Units on a body weight (Units/kg) basis ( see Data ). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.  The background risk of major birth defects and miscarriage for the indicated population is unknown. Data Animal Data In a study in which pregnant rats received daily intramuscular injections of DYSPORT (2.2, 6.6, or 22 Units/kg on gestation days 6 through 17 or intermittently 44 Units/kg on gestation days 6 and 12 only) during organogenesis, increased early embryonic death was observed with both schedules at the highest tested doses (22 and 44 Units/kg), which were associated with maternal toxicity.  The no-effect dose for embryo-fetal developmental toxicity was 2.2 Units/kg (less than maximum recommended human [MRHD] on a body weight basis). In a study in which pregnant rabbits received daily intramuscular injections of DYSPORT®  (0.3, 3.3 or 6.7 Units/kg) on gestation days 6 through 19 or intermittently (13.3 Units/kg on gestation days 6 and 13 only) during organogenesis, no embryofetal data were available at the highest dose administered daily (6.7 Units/kg) because of premature death in all does at that dose.  At the lower daily doses or with intermittent dosing, no adverse developmental effects were observed.  All dosed for which data were available are less than the MRHD on a body weight basis. In a study in which pregnant rats received 6 weekly intramuscular injections of DYSPORT (4.4, 11.1, 22.2, or 44 Units/kg) beginning on day 6 of gestation and continuing through parturition to weaning, an increase in stillbirths was observed at the highest dose tested, which was maternally toxic.  The no-effect dose for pre- and post-natal development toxicity was 22.2 Units/kg (similar to the MRHD). Risk Summary There are no data on the presence of DYSPORT in human or animal milk, the effects on the breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother's clinical need for DYSPORT and any potential adverse effects on the breastfed infant from DYSPORT  or from the underlying maternal condition. Infertility                               In rats, DYSPORT produced adverse effects on mating behavior and fertility [ see Nonclinical Toxicology (13.1 )]. Cervical Dystonia Safety and effectiveness in pediatric patients have not been established [see Boxed Warning and Warnings and Precautions (5.2) ]. Glabellar Lines DYSPORT is not recommended for use in pediatric patients less than 18 years of age. Spasticity Safety and effectiveness have been established in pediatric patients 2 years of age and older [see Warnings and Precautions (5.1), Adverse Reactions (6.1), and Clinical Studies (14.4)].   The safety and effectiveness of DYSPORT have been established by evidence from adequate and well-controlled studies of DYSPORT in patients 2 years of age and older with upper and lower limb spasticity.  The safety and effectiveness of DYSPORT injected into proximal muscles of the lower limb for the treatment of spasticity in pediatric patients has not been established [see Boxed Warning, Warnings and Precautions (5.2),  and Adverse Reactions (6.1)]. Safety and effectiveness in pediatric .below the age of 2 years have not been established [see Boxed Warning and  Warnings and Precautions (5.2)]. Juvenile Animal Data In a study in which juvenile rats received a single intramuscular injection of DYSPORT (1, 3 or 10 Units/animal) on postnatal day 21, decreased growth and bone length (injected and contralateral limbs), delayed sexual maturation, and decreased fertility were observed at the highest dose tested, which was associated with excessive toxicity during the first week after dosing. In a study in which juvenile rats received weekly intramuscular injections of DYSPORT (0.1, 0.3, or 1.0 Units/animal) from postnatal day 21 to 13 weeks of age, decreases in bone mineral content in the injected limb, associated with atrophy of injected and adjacent muscles, were observed at the highest dose tested.  No adverse effects were observed on neurobehavioral development.  However, dose levels were not adjusted for growth of the pups.  On a body weight basis, the doses at the end of the dosing period were approximately 15% of those at initiation of dosing.  Therefore, the effects of DYSPORT throughout postnatal development were not adequately evaluated. Cervical Dystonia There were insufficient numbers of patients aged 65 years and over in the clinical studies to determine whether they respond differently than younger patients.  In general, elderly patients should be observed to evaluate their tolerability of DYSPORT, due to the greater frequency of concomitant disease and other drug therapy [ see Dosage and Administration (2.3) ]. Glabellar Lines Of the total number of subjects in the placebo-controlled clinical studies of DYSPORT, 8 (1%) were 65 years and over.  Efficacy was not observed in subjects aged 65 years and over [ see Clinical Studies (14.2) ].  For the entire safety database of geriatric subjects, although there was no increase in the incidence of eyelid ptosis, geriatric subjects did have an increase in the number of ocular adverse reactions compared to younger subjects (11% vs. 5%) [ see Dosage and Administration (2.4) ]. Adult Spasticity Upper Limb Spasticity Of the total number of subjects in placebo-controlled clinical studies of DYSPORT, 30 percent were aged 65 years and over, while 8 percent were aged 75 years and over.  No overall differences in safety or effectiveness were observed between these subjects and younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals can not be ruled out. Lower Limb Spasticity Of the total number of subjects in placebo controlled clinical studies of DYSPORT, 18% (n=115) were 65 and over, while 3% (n=20) were 75 and over.  Subjects aged 65 years and over who were treated with DYSPORT reported a greater percentage of adverse reactions as compared to younger subjects (46% versus 39%).  Fall and asthenia were observed with greater frequency in older subjects, as compared to those younger (10% versus 6% and 4% versus 2%, respectively). Exploratory analyses in trials for glabellar lines in African-American subjects with Fitzpatrick skin types IV, V, or VI and in Hispanic subjects suggested that response rates at Day 30 were comparable to and no worse than the overall population.

DYSPORT® (abobotulinumtoxinA) for Injection is a sterile, lyophilized powder supplied in a single-dose, glass vial. Unopened vials of DYSPORT must be stored refrigerated between 2°C to 8°C (36°F to 46°F). Protect from light. Do not use after the expiration date on the vial. All vials, including expired vials, or equipment used with DYSPORT   should be disposed of carefully as is done with all medical waste. DYSPORT contains a unique hologram on the carton. If you do not see the hologram, do not use the product. Instead contact 855-463-5127. Cervical Dystonia, Spasticity in Adults, and Pediatric Patients 500 Unit Vial Each vial contains 500 Units of freeze-dried abobotulinumtoxinA. Box containing 1 vial—NDC 15054-0500-1 Box containing 2 vials—NDC 15054-0500-2 300 Unit Vial Each vial contains 300 Units of freeze-dried abobotulinumtoxinA. Box containing 1 vial—NDC 15054-0530-6 Glabellar Lines Each vial contains 300 Units of freeze-dried abobotulinumtoxinA. Box containing 1 vial— NDC 0299-5962-30

DYSPORT inhibits release of the neurotransmitter, acetylcholine, from peripheral cholinergic nerve endings. Toxin activity occurs in the following sequence: Toxin heavy chain mediated binding to specific surface receptors on nerve endings, internalization of the toxin by receptor mediated endocytosis, pH-induced translocation of the toxin light chain to the cell cytosol and cleavage of SNAP25 leading to intracellular blockage of neurotransmitter exocytosis into the neuromuscular junction. This accounts for the therapeutic utility of the toxin in diseases characterized by excessive efferent activity in motor nerves. Recovery of transmission occurs gradually as the neuromuscular junction recovers from SNAP25 cleavage and as new nerve endings are formed. The primary pharmacodynamic effect of DYSPORT is due to chemical denervation of the treated muscle resulting in a measurable decrease of the compound muscle action potential, causing a localized reduction of muscle activity. Using currently available analytical technology, it is not possible to detect DYSPORT in the peripheral blood following intramuscular injection at the recommended doses.

Carcinogenesis Studies to evaluate the carcinogenic potential of DYSPORT have not been conducted. Mutagenesis Genotoxicity studies have not been conducted for DYSPORT. Impairment of Fertility In a fertility and early embryonic development study in rats in which either males (2.9, 7.2, 14.5 or 29 Units/kg) or females (7.4, 19.7, 39.4 or 78.8 Units/kg) received weekly intramuscular injections prior to and after mating, dose-related increases in pre-implantation loss and reduced numbers of corpora lutea were noted in treated females. Failure to mate was observed in males that received the high dose. The no-effect dose for effects on fertility was 7.4 Units/kg in females and 14.5 Units/kg in males (approximately one-half and equal to, respectively, the maximum recommended human dose of 1000 Units on a body weight basis).

The efficacy of DYSPORT was evaluated in two randomized, double-blind, placebo-controlled, single-dose, parallel-group studies in treatment-naive cervical dystonia patients. The principal analyses from these trials provide the primary demonstration of efficacy involving 252 patients (121 on DYSPORT, 131 on placebo) with 36% male and 64% female. Ninety-nine percent of the patients were Caucasian. In both placebo-controlled studies (Study 1 and Study 2), a dose of 500 Units of DYSPORT was given by intramuscular injection divided among two to four affected muscles. These studies were followed by long-term open-label extensions that allowed titration in 250 Unit steps to doses in a range of 250 to 1000 Units, after the initial dose of 500 Units. In the extension studies, re-treatment was determined by clinical need after a minimum of 12 weeks. The median time to re-treatment was 14 weeks and 18 weeks for the 75 th percentile. The primary assessment of efficacy was based on the total Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) change from baseline at Week 4 for both studies. The scale evaluates the severity of dystonia, patient-perceived disability from dystonia, and pain. The adjusted mean change from baseline in the TWSTRS total score was statistically significantly greater for the DYSPORT group than the placebo group at Weeks 4 in both studies (see Table 14) . Table 14: TWSTRS Total Score Efficacy Outcome from the Phase 3 Cervical Dystonia Studies Intent to Treat Population  Study 1 Study 2 DYSPORT 500 Units N=55 Placebo N=61 DYSPORT 500 Units N=37 Placebo N=43 Baseline (week 0) Mean (SD) 43.8 (8.0) 45.8 (8.9) 45.1 (8.7) 46.2 (9.4) Week 4 Mean (SD) Change from Baseline Change from baseline is expressed as adjusted least square mean (SE) 30.0 (12.7) -15.6 (2.0) 40.2 (11.8) -6.7 (2.) 35.2 (13.8) -9.6 (2.0) 42.4 (12.2) -3.7 (1.8) treatment difference 95% confidence interval -8.9 Significant at p -value < 0.05 [-12.9 to -4.7] -5.9 [-10.6 to -1.3] Week 8 Mean (SD) Change from Baseline 29.2 (11.0) -14.7 (2.0) 39.6 (13.5) -5.9 (2.0) treatment difference 95% confidence interval -8.8 [-12.9 to -4.7] Analyses by gender, weight, geographic region, underlying pain, cervical dystonia severity at baseline and history of treatment with botulinum toxin did not show any meaningful differences between groups. Table 15 indicates the average DYSPORT dose, and percentage of total dose, injected into specific muscles in the pivotal clinical trials. Table 15: DYSPORT 500 Units starting dose (units and % of the total dose) by Unilateral Muscle Injected During Double-blind Pivotal Phase 3 studies 2 and 1 Combined    Number of patients injected per muscle Total number of patients in combined studies 2 and 1 who received initial treatment = 121. DYSPORT Dose Injected Percentage of the total DYSPORT Dose Injected     Median [DYSPORT Units] (min, max) 75th percentile [DYSPORT Units] Median [%] (min, max) 75th percentile [%] Sternocleidomastoid 90 125 Units (50, 350) 150 Units 26.5% (10, 70) 30.0% Splenius capitis 85 200 Units (75, 450) 250 Units 40.0%  (15, 90) 50.0% Trapezius 50 102.6 Units (50, 300) 150 Units 20.6% (10, 60) 30.0% Levator scapulae 35 105.3 Units (50, 200) 125 Units 21.1% (10, 40) 25.0% Scalenus (medius and anterior) 26 115.5 Units (50, 300) 150 Units 23.1% (10,60) 30.0% Semispinalis capitis 21 131.6 Units (50, 250) 175 Units 29.4% (10, 50) 35.0% Longissimus 3 150 Units (100, 200) 200 Units 30.0% (20, 40) 40.0% Three double-blind, randomized, placebo-controlled, clinical studies evaluated the efficacy of DYSPORT for use in the temporary improvement of the appearance of moderate to severe glabellar lines. These three studies enrolled healthy adults (ages 19-75) with glabellar lines of at least moderate severity at maximum frown. Subjects were excluded if they had marked ptosis, deep dermal scarring, or a substantial inability to lessen glabellar lines, even by physically spreading them apart. The subjects in these studies received either DYSPORT or placebo. The total dose was delivered in equally divided aliquots to specified injection sites (see Figure 1 ). Investigators and subjects assessed efficacy at maximum frown by using a 4-point scale (none, mild, moderate, severe). Overall treatment success was defined as post-treatment glabellar line severity of none or mild with at least 2 grade improvement from Baseline for the combined investigator and subject assessments (composite assessment) on Day 30 (see Table 16). Additional endpoints for each of the studies were post-treatment glabellar line severity of none or mild with at least a 1 grade improvement from Baseline for the separate investigator and subject assessments on Day 30. After completion of the randomized studies, subjects were offered participation in a two-year, open-label re-treatment study to assess the safety of multiple treatments. Table 16: Treatment Success at Day 30 (None or Mild with at least a 2 Grade Improvement from Baseline at Maximum Frown for the combined Investigator and Subject Assessments (Composite))   2 Grade Improvement Study DYSPORT n/N (%) Placebo n/N (%) GL-1 58/105 (55%) 0/53 (0%) GL-2 37/71 (52%) 0/71 (0%) GL-3 120/200 (60%) 0/100 (0%) Treatment with DYSPORT reduced the severity of glabellar lines for up to four months. Study GL-1 Study GL-1 was a single-dose, double-blind, multicenter, randomized, placebo-controlled study in which 158 previously untreated subjects received either placebo or 50 Units of DYSPORT, administered in five aliquots of 10 Units (see Figure 1   ). Subjects were followed for 180 days. The mean age was 43 years; most of the subjects were women (85%), and predominantly Caucasian (49%) or Hispanic (47%). At Day 30, 55% of DYSPORT-treated subjects achieved treatment success: a composite 2 grade improvement of glabellar line severity at maximum frown ( Table 16). In study GL-1, the reduction of glabellar line severity at maximum frown was greater at Day 30 in the DYSPORT group compared to the placebo group as assessed by both Investigators and subjects (Table 17). Table 17: GL-1: Investigators' and Subjects' Assessment of Glabellar Line Severity at Maximum Frown Using a 4-point Scale (% and Number of Subjects with Severity of None or Mild)   Investigators' Assessment Subjects' Assessment Day DYSPORT N=105 Placebo N=53 DYSPORT N=105 Placebo N=53 14 90% 95 17% 9 77% 81 9% 5 30 88% 92 4% 2 74% 78 9% 5 60 64% 67 2% 1 60% 63 6% 3 90 43% 45 6% 3 36% 38 6% 3 120 23% 24 4% 2 19% 20 6% 3 150 9% 9 2% 1 8% 8 4% 2 180 6% 6 0% 0 7% 7 8% 4 Study GL-2 Study GL-2 was a repeat-dose, double-blind, multicenter, placebo-controlled, randomized study. The study was initiated with two or three open-label treatment cycles of 50 Units of DYSPORT administered in five aliquots of 10 Units DYSPORT   (see Figure 1 ). After the open-label treatments, subjects were randomized to receive either placebo or 50 Units of DYSPORT.  Subjects could have received up to four treatments through the course of the study. Efficacy was assessed in the final randomized treatment cycle. The study enrolled 311 subjects into the first treatment cycle and 142 subjects were randomized into the final treatment cycle. Overall, the mean age was 47 years; most of the subjects were women (86%) and predominantly Caucasian (80%). At Day 30, 52% of DYSPORT - treated subjects achieved treatment success: a composite 2 grade improvement of glabellar line severity at maximum frown (see Table 16). The proportion of responders in the final treatment cycle was comparable to the proportion of responders in all prior treatment cycles. After the final repeat treatment with DYSPORT, the reduction of glabellar line severity at maximum frown was greater at Day 30 in the DYSPORT group compared to the placebo group as assessed by both Investigators and subjects (see Table 18). Table 18: GL-2 Investigators' and Subjects' Assessments of Glabellar Line Severity at Maximum Frown Using a 4-point Scale (% and Number of Subjects with Severity of None or Mild)   Investigators' Assessment Subjects' Assessment Day DYSPORT N=71 Placebo N=71 DYSPORT N=71 Placebo N=71 30 85% 60 4% 3 79% 56 1% 1 Study GL-3 Study GL-3 was a single-dose, double-blind, multicenter, randomized, placebo-controlled study in which 300 previously untreated subjects received either placebo or 50 Units of DYSPORT, administered in five aliquots of 10 Units (see Figure 1   ). Subjects were followed for 150 days. The mean age was 44 years; most of the subjects were women (87%), and predominantly Caucasian (75%) or Hispanic (18%). At Day 30, 60% of DYSPORT-treated subjects achieved treatment success: a composite 2 grade improvement of glabellar line severity at maximum frown (see Table 16). In study GL-3, the reduction of glabellar line severity at maximum frown was greater at Day 30 in the DYSPORT group compared to the placebo group as assessed by both Investigators and subjects (see Table 19). Table 19: GL-3 Investigators' and Subjects' Assessment of Glabellar Line Severity at Maximum Frown Using a 4-point Scale (% and Number of Subjects with Severity of None or Mild)   Investigators' Assessment Subjects' Assessment Day DYSPORT N=200 Placebo N=100 DYSPORT N=200 Placebo N=100 14 83% 166 5% 5 83% 165 2% 2 30 86% 171 0% 0 82% 163 2% 2 60 75% 150 1% 1 65% 130 4% 4 90 51% 102 1% 1 46% 91 2% 2 120 29% 58 1% 1 31% 61 3% 3 150 16% 32 1% 1 16% 31 3% 3 Geriatric Subjects In GL1, GL2, and GL3, there were 8 subjects aged 65 and older who were randomized to DYSPORT 50 Units in 5 equal aliquots of 10 Units (4) or placebo (4). None of the geriatric DYSPORT subjects were a treatment success at maximum frown at Day 30. Upper Limb Spasticity The efficacy and safety of DYSPORT for the treatment of upper limb spasticity in adults was evaluated in a randomized, multicenter, double-blind, placebo-controlled study that included 238 patients (159 DYSPORT and 79 placebo) with upper limb spasticity (Modified Ashworth Scale (MAS) score ≥2 in the primary targeted muscle group for toxin-naive patients or MAS score ≥3 in the primary targeted muscle group for toxin non-naive patients at least 4 months after the last botulinum toxin injection, of any serotype) who were at least 6 months post-stroke or post-traumatic brain injury.  The median age of the patients in this study was 55 years (range 18 to 78 years), 64% were male, and 86% were Caucasian. DYSPORT 500 Units (N=80), DYSPORT 1000 Units (N=79), or placebo (N=79) was injected intramuscularly into the affected upper limb muscles. After injection of the primary targeted muscle groups (PTMG), the remainder of the dose was injected into at least two additional upper limb muscles determined by the patient's individual presentation.  Table 20 provides the mean and range of DYSPORT doses injected and the number of injections into specific muscles of the upper limb. Table 20: DYSPORT Dose Injected and Number of Injections per Muscle in Adults with Upper Limb Spasticity Muscle DYSPORT Treatment Group Number of Patients Mean DYSPORT Units injected (Min, Max) Number of Injection Sites Median [Q1 ; Q3] Flexor digitorum  profundus (FDP)* 500 U 1000 U 54 65 93.5 Units (50 to 100) 195.5 Units (100 to 300) 1, [1 ; 2] 2, [1 ; 2] Flexor digitorum superficialis (FDS)* 500 U 1000 U 63  73 95.4 Units (50 to 100) 196.8 Units (100 to 300) 2, [1 ; 2] 2, [1 ; 2] Flexor carpi radialis (FCR)* 500 U 1000 U 57 57 92.2 Units (25 to 100) 178.1 Units (80 to 300) 1, [1 ; 2] 1, [1 ; 2] Flexor carpi ulnaris (FCU)* 500 U 1000 U 47 49 89.9 Units (25 to 180) 171.2 Units (80 to 200) 1, [1 ; 2] 1, [1 ; 2] Brachialis* 500 U 1000 U 60 43 148.5 Units (50 to 200)  321.4 Units (100 to 300) 2, [1 ; 2] 2, [1 ; 2] Brachioradialis* 500 U 1000 U 42 28 88.3 Units (50 to 200)  172.1Units (50 to 200) 1, [1 ; 2] 1, [1 ; 2] Biceps Brachii (BB) 500 U 1000 U 28 19 106.4 Units (50 to 200)  207.4 Units (100 to 400) 2, [1 ; 2] 2, [1 ; 2] Pronator Teres 500 U 1000 U 14 30 81.8 Units (45 to 200)  157.3 Units (80 to 200) 1, [1 ; 2] 1, [1 ; 2] *Primary Targeted Muscle Group The co-primary efficacy variables were muscle tone assessed by the MAS at the primary targeted muscle group at week 4 and the Physician Global Assessment (PGA; ranges from -4 = marked worse to +4 = marked improved) at week 4 (see Table 21). Table 21: Primary Endpoints (PTMG MAS and PGA) and MAS by Muscle Group at Week 4 in Adults with Upper Limb Spasticity   Placebo (N=79)  DYSPORT   (500 units) (N=80) (1000 units) (N=79) LS Mean Change from Baseline in PTMG Muscle Tone on the MAS -0.3 -1.2* -1.4* LS Mean PGA of Response to Treatment 0.7 1.4* 1.8* LS Mean Change from Baseline in Wrist Flexor Muscle Tone on the MAS -0.3 (n=54) -1.4 (n=57) -1.6 (n-58) LS Mean Change from Baseline in Finger Flexor Muscle Tone on the MAS -0.3 (n=70) -0.9 (n=66) -1.2 (n=73) LS Mean Change from Baseline in Elbow Flexor Muscle Tone on the MAS -0.3 (n=56) -1.0 (n=61) -1.2 (n=48) LS= Least Square *p≤0.05 Lower Limb Spasticity The efficacy of DYSPORT for the treatment of lower limb spasticity was evaluated in a randomized, multicenter, double-blind, placebo-controlled study that included 381 patients (253 DYSPORT and 128 placebo). Patients had lower limb spasticity (Modified Ashworth Scale (MAS) score ≥2 in the affected ankle joint for toxin-naive patients, or MAS score ≥3 in the affected ankle joint for toxin non-naive patients) and were at least 6 months post-stroke or post-traumatic brain injury.   Table 22 provides the median DYSPORT doses injected and the number of injections into specific muscles of the lower limb as reported in the double-blind study. In the study, the gastrocnemius and soleus muscles, and at least one additional lower limb muscle were injected, according to the clinical presentation.   Table 22:  DYSPORT Dose Injected and Number of Injections per Muscle in the Lower Limb - Median for the 1000 Unit and 1500 Unit Dose Groups Injected Muscle DYSPORT Units Injected Number of Injection Sites Gastrocnemius    Lateral    Medial 100 Units to 150 Units 1 100 Units to 150 Units 1 Soleus 333 Units to 500 Units 3 Tibialis posterior 200 Units to 300 Units 2 Flexor digitorum longus 133 Units to 200 Units 1 to 2 Flexor hallucis longus 67 Units to 200 Units 1 The primary efficacy variable was muscle tone assessed by the MAS at the ankle joint at week 4.  The first secondary endpoint was the Physician Global Assessment at week 4 (see Table 23). Table 23:  Primary Endpoint Change in MAS and the First Secondary Endpoint PGA at Week 4 in Adults with Lower Limb Spasticity LS Mean Change from Baseline on the Modified Ashworth Scale DYSPORT 1000 Units (N=125) DYSPORT 1500 Units (N=128) Placebo (N=128)   Week 4 -0.6 -0.8 P‹0.05 -0.5 LS Mean Physician Global Assessment Score Investigator   Week 4 0.9 0.9 0.7 Upper Limb Spasticity in Pediatric Patients The efficacy of DYSPORT for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age was evaluated in a double-blind, low-dose controlled, multicenter study (NCT02106351). A total of 208 patients with spasticity because of cerebral palsy who were toxin naïve or non-naïve (66% had prior treatment with botulinum toxin), weighed at least 10 kgs, and had a baseline Modified Ashworth Score (MAS) of grade 2 or greater (99% patients) at the primary targeted muscle groups (PTMG), were enrolled in the modified Intention to Treat population (mITT).  Patients received DYSPORT 16 Units/kg (n=70), DYSPORT 8 Units/kg (n=69), or DYSPORT 2 Units/kg (n=69) injected into the upper limb. The elbow flexors and wrist flexors respectively were the PTMG in 57% and in 43% of patients. The median age of the patients in this study was 9 years (range 2 to 17 years; 57% were between 2 and 9 years of age); 60% of patients were male, and 75% were White.    The primary efficacy endpoint was the mean change from baseline in MAS in the PTMG at Week 6 (see Table 24). The secondary efficacy endpoint was the mean Physician Global Assessment (PGA) score assessed at Week 6 (Table 25). Although PGA scores numerically favored DYSPORT treatment over the low-dose control, the difference was not statistically significant. Table 24:  Modified Ashworth Scale Score in the PTMG Change from Baseline at Week 6 in Pediatric Patients with Upper LImb Spasticity (mITT Population) Control Group Treatment Groups DYSPORT 2 U/kg (N=69) DYSPORT 8 U/kg (N=69) DYSPORT 16 U/kg (N=70) Baseline          Mean (SD) 3.1 (0.3) 3.1 (0.3) 3.1 (0.5) Week 6        LS a mean change from baseline in PTMG b on MAS  -1.6 -2.0 -2.3        Difference from control in LS a means -0.4 -0.7         p-value c 0.0118 d <0.0001   Week 16         LS a mean change from baseline in PGMG b on MAS -0.9 -1.2 -1.5        Difference from control in LS a means -0.3 d -0.6 d a LS = Least Square b PTMG=Primary Targeted Muscle Group c p-value is derived from ANCOVA on ranked MAS score change from baseline with treatment, baseline score, age range at baseline, prior botulinum toxin treatment status at baseline, and center as explanatory variables d Nominal p-value <0.05 Table 25: Physician Global Assessment of Treatment Response at Week 6 in Pediatric Patients with Upper Limb Spasticity (mITT Population) Control Group Treatment Group DYSPORT 2 U/kg (N=68) DYSPORT 8 U/kg (N=69) DYSPORT 16 U/kg (N=70) Week 6         Mean score (SD) 1.7 (0.9) 2.0 (0.9) 2.0 (0.9)         LS a mean in PGA 1.8 2.0 2.0         Difference from control in LS a mean 0.2 0.2        p-value b 0.2043 0.1880 Week 16       Mean score (SD) 1.7 (1.0) 1.6 (1.1) 1.9 (1.2)        LS a mean in PGA 1.8 1.7 1.9       Difference from contron in LS a mean -0.1 0.1       p-value b 0.7001 0.4041 a LS=Least Square b p-value is derived from ANOVA on ranked PGA score with treatment, age range at baseline, prior botulinum toxin treatment status at baseline, and center as explanatory variables Lower Limb Spasticity in Pediatric Patients The efficacy of DYSPORT for the treatment of lower limb spasticity in patients 2 to 17 years of age was evaluated in a double-blind, placebo-controlled, multicenter study.  A total of 235 patients with cerebral palsy causing dynamic equinus foot deformity who were toxin-naïve or non-naïve and had a Modified Ashworth Score (MAS) of grade 2 or greater at the ankle plantar flexors were enrolled.  Patients received DYSPORT 10 Units/kg/leg (n=79), DYSPORT 15 Units/kg/leg (n=79) or placebo (n=77) injected into the gastrocnemius and soleus muscles (see Table 27). Forty-one percent of patients (n=66) were treated bilaterally and received a total lower limb DYSPORT dose of either 20 Units/kg (n=37) or 30 Units/kg (n=29). The median age of the patients in this study was 5 years (range 2 to 17 years); 60% of patients were male, and 73% were Caucasian. The primary efficacy endpoint was the mean change from baseline in MAS in ankle plantar flexor at Week 4; a co-primary endpoint was the mean Physician’s Global Assessment (PGA) score at Week 4 (see Table 26). Table 26: MAS and PGA Change from Baseline at Week 4 in Pediatric Patient with Lower Limb Spasticity (ITT Population)     Placebo (N=77) DYSPORT 10 Units/kg/leg (N=79) DYSPORT 15 Units/kg/leg (N=79) LS Mean Change from Baseline in Ankle plantar flexor Muscle Tone on the MAS Week 4 -0.5 -0.9* -1.0* Week 12 -0.5 -0.8* -1.0* LS Mean PGA of Response to Treatment Week 4 0.7 1.5* 1.5* Week 12 0.4 0.8* 1.0* LS=Least Square *p‹0.05

GALDERMA Dysport ® (AbobotulinumtoxinA) for injection For intramuscular use                   300 UNITS/SINGLE-DOSE VIAL 1 VIAL WARNING: Dosing units of botulinum toxins are not interchangeable between commercial products NDC 0299-5962-30 Rx only